Let's talk medical research

With the outbreak of COVID-19, everyone is suddenly finding themselves living in uncertain times. Businesses are closed, schools are cancelled — but what about your clinical trial? 

[Updated June 2019]

With clinical trial protocols becoming ever more complex, it can feel like it’s never been more difficult to find patients who are both eligible for and interested in a particular clinical trial. Traditional methods of recruitment are becoming less impactful, which is why it’s time to consider a new approach: precision recruitment.

For years, clinical trial patient recruitment has looked the same: identify eligibility criteria for a single trial, conduct traditional media outreach, screen patients for that trial, and hope for the best. Increasingly, however, sponsors have been turning to technology, getting more specific in their outreach and therefore becoming more successful in their recruiting not just for one trial, but ...

One of the most frustrating elements of medical research today is the speed — patients need new treatments now, but often, clinical trials are delayed or closed due to difficulty finding patients to take part. With clinical trial patient recruitment, sponsors can not only meet deadlines, but beat them, bringing new treatments to patients faster. Here, we break down the key reasons to set your ...

Last week, we had the pleasure of listening in to an important webinar hosted by FasterCures called “The Game-Changing Impact of Empowering Patients with Health Data.” Moderated by FasterCures’ Executive Director, Tanisha Carino, the online panel discussed the importance of patient access to health data, while walking through potential privacy concerns and other pitfalls that accompany access. On ...

Clinical trial patient recruitment can be difficult for Alzheimer's disease trials, particularly for prodromal Alzheimer's. Increasingly, sponsors are turning to Alzheimer's patient registries for help. Here, we'll share an Alzheimer's registry recruitment case study that demonstrates the need for community engagement and precision matching for these types of projects.

While you’re at the pharmacy picking up a medication you’ve been prescribed, you might not be thinking about all of the research that went into making that treatment available to you. On average, it takes at least ten years for a new medicine to make it to market, and six to seven of those years involve clinical trials. It’s important to understand all that goes into developing drugs, so that you ...

BIO International Conference happened earlier this month in Boston. Antidote was there among more than 45,000 attendees to network, share ideas, learn new technologies, and be inspired. It’s a conference that fosters collaboration between top industry players and advocacy organizations alike, on a massive scale.

The clinical trial landscape is shifting — but is it enough? Antidote’s Founder, Pablo Graiver, was recently interviewed for the Relentless Health Value podcast to discuss this fundamental question.